The medical news that matters, in five minutes.

Daily digest

Saturday, October 24, 2026

A first-of-its-kind hepatitis B approval, a CAR-T autoimmune trial death, and ESMO's cancer-vaccine moment

1. 01

   FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment

   Source: FDA

   FDA approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus infection in certain adults without cirrhosis. BioPharma Dive reports the GSK/Ionis drug is viewed as a potential 'functional cure' for chronic infection.

   Why it mattersA new mechanism added on top of standard antivirals changes the HBV treatment conversation for hepatologists, and a new product means a new label, risk-management plan and post-marketing safety surveillance to watch.
2. 02

   Patient dies in Bristol Myers Squibb autoimmune CAR-T trial

   Source: STAT

   STAT reports a patient death in a Bristol Myers Squibb trial of CAR-T therapy for an autoimmune condition, and asks where the safety bar should sit for these studies (full story is STAT+).

   Why it mattersAutoimmune patients are not facing the same risk-benefit trade-off as patients with refractory cancer, so serious events in this setting will shape regulator, IRB and sponsor tolerance for the whole CAR-T-in-autoimmunity field.
3. 03

   Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

   Source: BioPharma Dive

   In a landmark melanoma study, the Moderna/Merck personalized cancer vaccine (intismeran) plus Keytruda cut the risk of relapse or death by 42%, a result that met Wall Street expectations but triggered a 'sell-the-news' share drop.

   Why it mattersThis is a key test of individualized mRNA cancer vaccines in the adjuvant setting; oncologists will want the full ESMO data, and regulators a first look at a new class with its own manufacturing and safety questions.

   Market news · Not investment advice

4. Advertise here · reach clinicians, pharma & health brands →
5. 04

   Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2)

   Source: The Lancet

   In two randomised trials, Novartis's oral BTK inhibitor remibrutinib was superior to teriflunomide in relapsing MS while maintaining a favourable safety profile, per the authors. STAT reports it cut relapse rates by a third versus the standard treatment.

   Why it mattersBTK inhibitors have faced liver-safety scrutiny as a class, so the hepatic safety detail in the full paper matters as much as efficacy for neurologists and drug-safety teams.
6. 05

   GLP-1 compounder issues recall for copycat Zepbound

   Source: BioPharma Dive

   A compounding pharmacy has recalled a compounded tirzepatide product that copies Zepbound, adding to concerns about knockoff weight-loss drugs that stay popular despite FDA warnings and legal pressure from Lilly and Novo.

   Why it mattersPatients on compounded GLP-1s may not be visible in brand pharmacovigilance data, so clinicians should ask what product patients are actually injecting when assessing adverse events.
7. 06

   Hospital Glucose Meter Removal: Nova Biomedical Removes StatStrip Glucose Hospital Meter Systems

   Source: FDA MedWatch

   FDA posted a removal notice for StatStrip Glucose Hospital Meter Systems, which need a software update because glucose results could be assigned to the wrong patient.

   Why it mattersA point-of-care result filed under the wrong patient can drive wrong insulin dosing; hospitals using StatStrip should confirm the software update and their barcode-scanning workflow.
8. Advertise here · reach clinicians, pharma & health brands →
9. 07

   Ebola vaccine trial begins in DR Congo

   Source: Medical Xpress (AFP)

   The first clinical trial of an Ebola vaccine in the outbreak gripping the Democratic Republic of Congo began on Friday, according to the head of the World Health Organization.

   Why it mattersRunning a trial inside an active outbreak is the fastest route to efficacy data, and the results will inform outbreak-response vaccine strategy across the region.
10. 08

    AMA and EMA issue joint guidance on Ebola vaccine development

    Source: EMA

    EMA's Emergency Task Force and the African Medicines Agency published a joint position paper to support the timely start of clinical trials for potential Ebola vaccines.

    Why it mattersAligned expectations from European and African regulators can cut the time to start trials in an outbreak, which is useful for sponsors planning emergency vaccine programmes.
11. 09

    Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

    Source: STAT

    A new analysis finds that most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit (full story is STAT+).

    Why it mattersThis adds pressure on approval and reimbursement standards in oncology and is relevant to HTA, market-access and benefit-risk discussions for new oncology filings.
12. Advertise here · reach clinicians, pharma & health brands →
13. 10

    FDA Launches New Program to Advance Neuroscience Medical Product Development

    Source: FDA

    FDA announced the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program it says is aimed at accelerating neuroscience medical product development.

    Why it mattersNeuroscience sponsors should watch for how NAIN changes early engagement with FDA and endpoint discussions; the specifics are in FDA's announcement.
14. 11

    La Roche-Posay to Neutrogena: New BEMT sunscreens hitting shelves in the US

    Source: Cosmetics Business

    Cosmetics Business reports that bemotrizinol (BEMT), the first new ingredient FDA has allowed in over-the-counter sunscreens in the US since 1999, is now in new products from brands including La Roche-Posay, Neutrogena and Ultra Violette.

    Why it mattersA new OTC sunscreen filter after decades is a consumer-health regulatory milestone; dermatologists will field patient questions, and brands will watch labeling and post-market experience.
15. 12

    L'Oréal hails 'exceptional' third quarter 2026 led by dermatological and professional beauty

    Source: Cosmetics Business

    L'Oréal, owner of CeraVe and Kérastase, reported growth across all divisions in Q3 2026, with what it called 'remarkable' performance in professional products and dermatological beauty (company-reported).

    Why it mattersDermatologist-recommended skincare is a key growth engine for the cosmetics industry, which keeps derm-cosmetic claims and their substantiation in the regulatory spotlight.
16. Advertise here · reach clinicians, pharma & health brands →
17. 13

    Abbott plans nutrition spinoff as Q3 sales improve

    Source: NutraIngredients

    Abbott announced plans to spin off its global nutrition business into an independent, publicly traded company by the end of 2027, alongside a mixed Q3 report that showed a 5.1% rise in worldwide nutrition sales.

    Why it mattersA standalone nutrition company (infant, adult and medical nutrition) would reshape the consumer-health and nutraceutical landscape and its partnerships with clinicians and ingredient suppliers.
18. 14

    Calcium-rich whey protein side stream delivers post-menopausal bone health benefits

    Source: NutraIngredients

    A new clinical study reported that 12 months of supplementation with a calcium-rich byproduct of whey protein production supported maintenance of bone mineral density in postmenopausal women.

    Why it mattersSupplement evidence is moving toward 12-month clinical endpoints such as BMD; clinicians should read the trial design before patients ask, and any marketing must stay within structure/function claims.
19. 15

    Gilead to pay $1.275B upfront for PepStar's oral IL-23 program

    Source: Fierce Biotech

    Gilead agreed to acquire global rights to Shanghai-based PepStar Therapeutics' oral IL-23 receptor inhibitor program, including phase 1 candidate HCXT-2001, for $1.275 billion upfront, positioning it against J&J's oral Icotyde.

    Why it mattersA large upfront for a phase 1 asset shows how hotly contested oral IL-23 blockade is in inflammatory bowel disease; Gilead says HCXT-2001 could pair with its α4β7 inhibitor emvistegrast for an all-oral combination. Not investment advice.

    Market news · Not investment advice

20. Advertise here · reach clinicians, pharma & health brands →
21. 16

    Genmab shares rise after Rina-S hits PFS and OS in phase 3 ovarian cancer trial

    Source: RTTNews

    Genmab shares gained about 10% on Friday after the phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer met its primary progression-free survival endpoint and key secondary overall survival endpoint, per RTTNews; Genmab reported a 71% reduction in risk of progression or death and 57% reduction in risk of death versus investigator's-choice chemotherapy.

    Why it mattersPlatinum-resistant ovarian cancer has few effective options, and an OS benefit for an FRα-targeted ADC is a strong regulatory and commercial signal; Genmab plans to discuss the data with regulators. Not investment advice.

    Market news · Not investment advice

22. 17

    EQT agrees to take diagnostics maker Qiagen private in ~$12.1B deal

    Source: TheBench.Bio

    EQT Private Equity agreed to acquire Qiagen for €46.50 per share in cash, valuing the company at about €10.8 billion ($12.1 billion) including debt; the companies expect the deal to close in mid-2027, subject to shareholder acceptance and regulatory clearances.

    Why it mattersOne of the year's biggest diagnostics and life-science tools take-privates; Qiagen's boards said private ownership could support longer-term investment. Not investment advice.

    Market news · Not investment advice